FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns application of 1-(hermatrane-1-yl)-1-oxyethylamine as an agent inhibiting total activity of the main (alkaline) phospholipase A2 of mononuclear cells.
EFFECT: invention provides inhibition of total activity of basic (alkaline) phospholipase A2 of mononuclear cells.
4 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2732881C1 |
| METHOD OF INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM | 2020 |
|
RU2732880C1 |
| USE OF BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2733166C1 |
| APPLICATION OF PROTATRAN 4-CHLORO-2-METHYLPHENOXYACETATE FOR EXHAUSTING OF MONONUCLEAR CELLS BASIC (ALKALINE) PHOSPHOLIPASE a2 TOTAL ACTIVITY | 2016 |
|
RU2619860C1 |
| USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
| METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| 1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
